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Abstract
Background: In Sri Lanka, there exists chronic kidney disease of both known (CKD) and unknown etiologies (CKDu).
Identification of novel biomarkers that are customized to the specific causative factors would lead to early diagnosis
and clearer prognosis of the diseases. This study aimed to find genetic biomarkers in blood to distinguish and
identify CKDu from CKD as well as healthy populations from CKDu endemic and non-endemic areas of Sri Lanka.
Methods: The expression patterns of a selected panel of 12 potential genetic biomarkers were analyzed in blood
using RT-qPCR. Fold changes of gene expressions in early and late stages of CKD and CKDu patients, and an
apparently healthy population of a CKDu endemic area, Girandurukotte (GH) were calculated relative to apparently
healthy volunteers from a CKDu non-endemic area, Kandy (KH) of Sri Lanka, using the comparative CT method.
Results: Significant differences were observed between KH and early stage CKDu for both the insulin-like growth
factor binding protein 1 (IGFBP1; p = 0.012) and kidney injury molecule-1 (KIM1; p = 0.003) genes, and KH and late
stage CKD and CKDu for the glutathione-S-transferase mu 1 (GSTM1; p < 0.05) gene. IGFBP1 and KIM1 genes
showed significant difference between the early and late stage CKDu (p < 0.01). The glutamate cysteine ligase
catalytic subunit (GCLC) gene had significantly different expression between KH and all the other study groups (p <
0.01). The GH group was significantly different from the KH group for the oxidative stress related genes, G6PD,
GCLC and GSTM1 (p < 0.01), and also the KIM1 gene (p = 0.003). IGFBP1, insulin-like growth factor binding protein 3
(IGFBP3), fibronectin 1 (FN1) and KIM1 showed significant correlations with serum creatinine, and IGFBP1, KIM1 and
kallikrein 1 (KLK1) with eGFR (p < 0.05).
Conclusion: A panel consisting of IGFBP1, KIM1, GCLC and GSTM1 genes could be used in combination for early
screening of CKDu, whereas these genes in addition with FN1, IGFBP3 and KLK1 could be used to monitor
progression of CKDu. The regulation of these genes has to be studied on larger populations to validate their
efficiency for further clinical use.
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Background
Chronic kidney disease (CKD) is increasing rapidly
worldwide and is gaining much attention in both the
developed as well as developing countries. CKD is char-
acterized by a reduced glomerular filtration rate (GFR)
that is accompanied with structural or functional
abnormalities of the kidneys on urinalysis, biopsy and
imaging [1].
The concept of biomarker discovery in medicine is be-
coming increasingly important due to its potential for
early screening, more effective treatment and a more
personalized approach to medical care [2].“A biological
marker (biomarker) is a characteristic that is objectively
measured and evaluated as an indicator of normal bio-
logical processes, pathogenic processes, or pharmaco-
logic responses to a therapeutic intervention.”[3] The
biomarkers could be identified at any level along the
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genome – phenome continuum, and could be genomic
biomarkers (DNA or RNA), proteomic biomarkers (pro-
teins) or metabolic biomarker (metabolites) [3].
Biomarkers in both acute kidney injury (AKI) and
CKD look for similar effects of the diseases; decrease in
nephron number, vascular insufficiency, and cell cycle
disruption [1]. The biomarkers of kidney disease should
however be complemented with clinical assessments of
patients with CKD and AKI and not be used in isolation
[1]. The intended biomarkers should provide rapid, non-
invasive and specific measurements that correlate well
with kidney tissue pathology [1].
The most sensitive marker of CKD progression in clin-
ical practice is proteinuria, especially when combined
with the estimated glomerular filtration rate (eGFR) [2];
however, the process of kidney injury starts with the in-
duction of molecular level changes, which therefore
gives promise for identification of molecular markers for
early diagnosis of disease process. Biomarkers are
needed in CKD to help estimate GFR, assess cardiovas-
cular disease, determine metabolic abnormalities associ-
ated with CKD and differentiate inflammatory and
fibrotic conditions of the kidney [1]. The etiologies for
CKD differ and therefore comorbidities exist in most
CKD patients, hence a single biomarker would be incap-
able of satisfying all these needs [1, 2].
In Sri Lanka, there exists CKD of known etiologies
(with the majority being diabetes and cardiovascular dis-
eases) and unknown etiology (CKDu). This CKDu is
confined to certain geographical locations of the coun-
try, notably the dry zones, in the North Central Province
and Uva Province where the majority of the population
are involved in farming as the main occupation. The ma-
jority of the hypotheses for the cause of the disease re-
volve around environmental stimuli based on the
environmental location and occupation of the affected
individuals [4–9]. The main biomarkers for screening
and identification of CKDu include dipstick proteinuria,
serum creatinine and eGFR measurements, while ex-
cluding known etiologies of CKD such as diabetes,
hypertension, and systemic lupus erythematosus [10].
The presence of small, echogenic kidneys, and tubuloin-
terstitial damage on renal biopsy further confirm diagno-
sis [11]. As with CKD, the identification of diseased
individuals takes place only in the later stages of the dis-
ease where the symptoms become apparent.
Although analyzing renal tissue samples would be
most ideal as it is the affected tissue, the obtaining of
biopsies is invasive, more expensive and not suitable
for initial screening purposes [12]. This brings about
a need for other suitable tissues for the safe, reliable
and inexpensive monitoring of biomarkers. Body
fluids like serum and urine are mainly targeted for
the identification of biomarkers as they are the least
invasive methods and replace the usage of tissue
biopsies [13].
In this pilot study, genes that have potential as screen-
ing and prognostic biomarkers of CKD, both known and
unknown etiology, were selected from literature to cover
more than one particular characteristic/function related
to the disease. The expression pattern of selected genes,
namely kidney injury molecule-1 (KIM1), fibronectin 1
(FN1), insulin like growth factor binding protein 1
(IGFBP1), insulin like growth factor binding protein 3
(IGFBP3), kallikrein 1 (KLK1), glutathione S transferase
mu 1 (GSTM1), glutamate cysteine ligase catalytic sub-
unit (GCLC), glucose-6-phosphate dehydrogenase
(G6PD), cytochrome P450 enzyme 2D6 (CYP2D6) and
2C19 (CYP2C19) were analyzed in both chronic kidney
disease patients of known and unknown etiology resid-
ing in Girandurukotte, a CKDu endemic area belonging
to the dry zone of Sri Lanka. The majority of cases in
this region belong to the CKDu category. Healthy indi-
viduals from the same area who are considered at risk
and have been previously screened for CKDu and found
negative, and healthy individuals from an area not en-
demic for CKDu, Kandy, located in the Central Province,
wet zone of the country were selected as controls.
Among the genes selected, two were related to kidney
injury and repair, KIM1 and FN1. KIM1 is a novel bio-
marker of kidney injury that is upregulated in dediffer-
entiated proximal tubule epithelial cells in kidney after
ischemic or toxic injury [14]. FN1 is a glycoprotein in-
volved in cell adhesion and migration process including
wound healing, blood coagulation and host defense. It
has also been linked to tissue scarring and fibrosis [15].
Metabolic disorders such as diabetes and cardiovascu-
lar diseases are either causative factors or complications
of chronic kidney diseases. Therefore three genes related
to cardiovascular complications and diabetes were se-
lected to observe their use as possible prognostic bio-
markers. IGFBP1and IGFBP3 belong to a family of
IGFBPs which has six proteins that specifically bind in-
sulin like growth factors I (IGF-I) and II (IGF-II). The
IGF system has been increasingly implicated in the de-
velopment of cardiovascular diseases [16]. They are
multifunctional as they not only passively circulate
transporters, but also play a variety of roles in the circu-
lation, extracellular environment, and inside the cell
[17]. IGFBP3 has the major IGF transport function and
is the most abundant circulating IGFBP. It has been sug-
gested to have a role of wound healing by binding to the
IGF-1 and releasing them at the wound sites [17].
KLK1 belongs to the kallikreins, a different group of
proteins, serine proteases that have been related to hu-
man essential hypertension and associated complica-
tions. Low levels of urinary kallikreins have been
associated with hypertension and renal disease [18].
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There have been hypotheses suggesting the possible
role of metal toxicity and environmental toxins as etio-
logical factors of CKDu in Sri Lanka [19]. We therefore
selected genes related to metal toxicity and oxidative
stress (GSTM1, GCLC and G6PD), and xenobiotic me-
tabolism (CYP2D6 and CYP2C19) which could be pos-
sibly influenced by the environmental toxins, in turn
acting as biomarkers of toxicity.
Glutathione (GSH) plays a crucial role in the antioxi-
dant defense system and has a predominant role in the
regulation of the intracellular redox state and protects
cells from oxidative injury [20]. Two genes related to
GSH were selected to be studied; GCLC, the rate limit-
ing enzyme in the production of GSH, and GSTM1, the
enzyme that facilitates the detoxification action of GSH
by providing a hydrophilic binding site for glutathione
and a hydrophobic binding site for electrophilic sub-
strates [21]. The G6PD enzyme is another protein that
enables cells to counterbalance the oxidative stress via
the activation of the glutathione system by the produc-
tion of nicotinamide adenine dinucleotide phosphate
(NADPH) [22].
Two genes belonging to the cytochrome P450 mono-
xygenase enzyme family, CYP2D6 and CYP2C19 were
selected to study any differential expression influenced
by drugs or xenobiotics. CYP2D6 metabolizes 20–25%
of the clinically used drugs [23], whereas CYP2C19 me-
tabolizes 8% of all drugs [24]. Such drug metabolizing
enzymes are not only expressed in liver tissue, but also
extra hepatic tissues like blood lymphocytes, kidney and
intestine [25]. Studies have shown that substrate metab-
olism and toxicity can be influenced by the xenobiotic
modulation of the CYP genes and that they could hence
be sensitive markers of chemical exposure [26, 27].
The expression patterns of the genes were tested in
the CKD, CKDu and apparently healthy, risk groups of
the CKDu endemic area in comparison to apparently
healthy individuals of a non-endemic area in order to
identify possible early screening and prognostic markers.
Methods
Patients
The patients to be studied were recruited from June
2013 to November 2015 from the Renal Care &
Research Centre, District Hospital, Girandurukotte, a re-
gion endemic for CKDu, located in the Uva Province,
belonging to the dry zone of Sri Lanka. The diagnosis of
patients was carried out by the nephrologist attending
the Renal Clinic of the hospital.
CKDu was labeled as having unknown etiology based
on criteria set by the Ministry of Health, Sri Lanka with
no past history of diabetes mellitus, chronic or severe
hypertension, snake bite, glomerulonephritis or uro-
logical diseases being causes for the disease. A normal
HBA1C (<6.5%), blood pressure <160/100 mmHg un-
treated or <140/90 mmHg on up to two antihypertensive
medications were additional features. The stages of
CKD/CKDu are classified according to the GFR levels
(Table 1) [28]. The serum creatinine is also used to esti-
mate the GFR (eGFR) levels [29] and therefore is an im-
portant biomarker of kidney injury. The equation used
was that proposed by Levey et al. [30] (Eq. 1).
eGFR ¼ 186
 serum creatinine mg=dLð Þ½ −1:154
 ageð Þ−0:203  0:742 if femaleð Þ ð1Þ
The patient population was categorized into four cat-
egories; early stage CKDu (n = 11), late stage CKDu (n =
23), early stage CKD(n = 5) and late stage CKD (n = 9),
where the early stages consisted of stage 1 to stage 3 pa-
tients and late stages consisted of stage 4 and stage 5
patients.
Healthy volunteers
Two apparently healthy groups were selected for the
study, consisting of volunteers from both the CKDu en-
demic region, Girandurukotte (GH; n = 5), located in the
Uva Province, dry zone of the country, as well as a re-
gion not endemic to CKDu, Kandy (KH; n = 7), located
in the Central Province, wet zone of the country. The
residents of Girandurukotte undergo routine screening
for CKD/u and the selected individuals were not identi-
fied as being diseased. However, the individuals of the
Girandurukotte healthy population, being of the same
environmental area, are considered to be under risk, due
to causative factors of CKDu being hypothesized as en-
vironmental related and therefore their expression pat-
terns were also analyzed with respect to the healthy
group from Kandy.
Sample collection and storage
Blood samples were collected during routine blood col-
lection from patients. Whole blood (1 mL) was collected
into 3 mL TRIzol LS reagent (Invitrogen), shaken vigor-
ously to ensure lysis and transported in ice from the Dis-
trict Hospital, Girandurukotte to the National Institute
Table 1 Different stages of chronic kidney disease classified by
glomerular filtration rates






Stage 5 <15 (or dialysis)
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of Fundamental Studies, Kandy, where it was stored
under −20 °C. RNA extractions were carried out the day
following arrival at the facility.
RNA extraction and RT-qPCR
RNA was extracted according to the TRIzol LS (Invitro-
gen) manufacturer’s protocol followed by purification
using PAXgene spin columns (PreAnalytix). All ex-
tracted RNA samples were checked for integrity by using
Agarose gel electrophoresis, and looking for 28 s:18 s
rRNA intensity of approximately 2:1. The absorbance
values, A280/A260 and A230/A260 were measured using
UV spectrophotometry (Shimadzu) to interpret protein
and salt impurities and values had to be greater than 1.7
and 1.0 respectively for inclusion in study. A total of
1 μg of RNA as measured by the QuantiFluor-ST RNA
system (Promega) was used in the preparation of cDNA
(Quantitect Reverse Transcription Kit, Qiagen). Equal
amount of cDNA (total RNA = 50 ng) was used in each
PCR reaction.
PCR Mastermix was prepared using the Quantitect
Probe PCR Kit (Qiagen) and reaction components
included 10 μL QuantiTect Probe PCR mastermix (Qia-
gen), 4 μL RNase free H2O, 0.8 μM forward and reverse
primers, 0.2 μM probe and 50 ng of cDNA template.
The cycler was programmed for initial activation of Hot-
StartTaq polymerase at 95 °C for 15 mins, and 50 cycles
of denaturation at 95 °C, 30s and combined annealing
and extension at 60 °C, 60s. Hydrolysis probes were used
for the fluorescent detection and quantification of PCR
amplification. Self designed as well as pre designed
primers were used for the PCR amplification [31–35].
Details of primers and probes used have been presented
in Table 2. The fluorescence for probe detection was ac-
quired in the extension steps using the green channel of
the RotorGene Q cycler (Qiagen).
Quantification of fold changes
Fold changes were calculated using the comparative Ct
method [36] with two reference genes, B2M and
GAPDH. The KH group was used for calibration. The
individual fold changes were calculated and geometric
means obtained of the respective groups.
Table 2 Details of primer and probe sequences
Name Accession Number Sequences 5’–3’
(F- forward, R- reverse, P- probe)
GCLC NM_001498.3 F: ACAAGGACGTTCTCAAGTG
R: AGGATGGTTTGGGTTTGTC
P: CCTGTCTGGGGAGAAAGTTCTTGAAACTCT
KIM1 NM_012206.2 F: AACCAGTAGCCACTTCAC
R: CTGTCACGGTGTCATTCC
P: TCAGCCAGCAGAAACCCACCC
GSTM1 NM_000561.3 F: GCATGATCTGCTACAATCCA
R: TTGTTTCCTGCAAACCAT
P: CCTGAAAAGCTAAAGCTCTACTCAGAG
KLK1 NM_002257.3 F: GGACTACAGCCACGACCTCATGCTGC
R: GTCCACACACTGGAGATCATCTGG
P: TGGAGTTGCCCACCGAGGAACCCGAA
CYP2D6 NM_000106.5 F: TAGTGGTGGCTGACCTGTTCTCT R: TCGTCGATCTCCTGTTGGACA
P: CTCCTGCTCATGATCCTACATCCGGA
CYP2C19 NM_000769.1 F: GAACACCAAGAATCGATGGACA
R: TCAGCAGGAGAAGGAGAGCATA
P: TAATCACTGCAGCTGACTTACTTGGAGCTGGG
IGFBP1 NM_000596.2 F: GGGACGCCATCAGTACC R: CCATTTTTTGATGTTGGTGAC
P: ATGATGGCTCGAAGGCTCTCCA
IGFBP3 NM_000598.4 F: CAGAGCACAGATACCCAGAACTTC R: TTCTCTACGGCAGGGACCAT
P: ATTCTGTCTCCCGCTTGGACTCGGA
FN1 NM_212482.1 F: GAAGAGCGAGCCCCTGAT R: GGGGTCTTTTGAACTGTGGA
P: AGACGAGCTTCCCCAACTGGTAACCCCTT
G6PD NM_000402.4 F: TGCCCCCGACCGTCTAC R: ATGCGGTTCCAGCCTATCTG
P: ACTCGTGAATGTTCTTGGTGACGGCC
B2M NM_004048.2 F: TGCCGTGTGAACCATGTGA R: CCAAATGCGGCATCTTCAA
P: TGATGCTGCTTACATGTCTCGATCCCACT
GAPDH NM_001289745.1 F: TGACCTCAACTACATGGTTTA
R: GCCCCACTTGATTTTGGA
P: CCATGGCACCGTCAAGGCTGA
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Statistical analysis
Log 2 normalized values of the fold changes were used
for further statistical analysis. One way ANOVA and
post hoc Games-Howell analysis were carried out to
identify significant results. Outliers, extreme of 1.5 times
of inter-quartile range (IQR), calculated separately for
each study group were excluded in ANOVA calculations.
The log 2 normalized fold changes were also analyzed
for correlation with the currently used marker of CKD,
serum creatinine, using the Pearson correlation coeffi-
cient and two tailed significance values. Missing values
were replaced with means for the correlation calcula-
tions. The correlations were carried out separately for
the CKD and CKDu groups.
Gender-wise difference in expression of the genes




The characteristics of the study population are summa-
rized in Table 3. A total of 60 subjects were included in
the study; 51 males and 9 females. The mean age of the
study population was 51 ± 12. The serum creatinine and
eGFR levels of the early stage CKDu were 1.62 ± 0.74
and 52.03 ± 22.52, and the late stage CKDu were 4.03 ±
2.52 and 21.61 ± 11.03 respectively. The serum creatinine
and eGFR levels of the early stage CKD were 1.28 ± 0.45
and 64.26 ± 21.25, and the late stage CKD were 3.72 ±
1.36 and 20.16 ± 7.46 respectively. The healthy popula-
tions from both the Girandurukotte as well as Kandy
areas were selected based on no current illnesses and no
previous records of chronic illnesses; their serum cre-
atinine and eGFR levels were not measured. There were
eight patients with hypertension, three patients with
diabetes, and three patients with both diabetes and
hypertension as causes for CKD. Three of the CKDu pa-
tients had asthma as a chronic illness. Majority of the
patient population (87.5%) were involved in farming ei-
ther directly or assisting. None of the healthy individuals
from both the endemic as well as non-endemic areas
who volunteered for the study were involved directly in
or assisted with farming.
Gene expression analysis
The expressions of the selected genes were analyzed in
the patient groups and the GH group using the KH
group as calibrators. Group means with standard errors
of log normalized values have been graphically presented
(Fig. 1).
Significant differences were seen on one-way
ANOVA, for four of the studied genes, IGFBP1 (F5,52
= 3.705, p = 0.007), KIM1 (F5,56 = 3.701, p = 0.006),
GCLC (F5,52 = 5.535, p = 0.000), GSTM1 (F5, 36 = 3.143,
p = 0.021) and KLK1 (F5, 55 = 2.925, p = 0.022). Post
hoc Games-Howell test, equal variances not assumed,
revealed significant difference between the KH group
and early stage CKDu for both the IGFBP1 gene (p =
0.012) and the KIM1 gene (p = 0.003), and KH group
and late stage CKDu and late stage CKD for the
GSTM1 gene (p = 0.021 and p = 0.030). Significant dif-
ference was seen between the early and late stage
CKDu for the IGFBP1 and the KIM1 genes (p = 0.010
and p = 0.006 respectively). The GCLC gene showed
significant differences in expression between the KH
group and all the other study groups (p < 0.05). The
GH population was significantly different from the
KH population for the three oxidative stress related
genes G6PD (p = 0.004), GCLC (p = 0.004) and












Healthy (n = 5)
Kandy Healthy
(n = 7)
Age 51 52 54 53 60 35 34
±12 ±5 ±8 ±17 ±6 ±8 ±9
Gender
Male 51 9 19 4 9 4 6
Female 9 2 4 1 0 1 1
Other Chronic Diseases
Hypertension 8 0 0 3 5 0 0
Diabetes 3 0 0 1 2 0 0
Hypertension + Diabetes 3 0 0 1 2 0 0
Asthma 3 2 1 0 0 0 0
Serum Cr 3.28 ± 2.20 1.62 ± 0.74 4.03 ± 2.51 1.28 ± 0.45 3.72 ± 1.36 - -
eGFR 30.81 ± 21.15 52.32 ± 22.64 21.73 ± 11.09 64.61 ± 21.36 20.27 ± 7.50 - -
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GSTM1 (p = 0.015), and also the KIM1 gene (p =
0.003). Significant difference between GH and late
stage CKDu was seen in the G6PD (p = 0.007) and
IGFBP1 (p = 0.013) genes.
Other significant results include absence of the
GSTM1 gene expression in 11/34 CKDu patients
(32.35%), 6/14 CKD patients (42.86%), 0/5 GH popula-
tion and 3/7 KH individuals (42.86%).
Correlation with currently used biomarkers
The log normalized gene expression was correlated
with two currently used markers of CKD; serum cre-
atinine and eGFR, separately in the CKD and CKDu
groups. Pearson correlation coefficients and two-tailed
significance values were calculated (Table 4; Table 5),
and correlation graphs plotted (Figs. 2, 3) respectively
for CKD and CKDu. No significant correlations were
Fig. 1 Group means with standard errors of log normalized gene expressions of a CYP2D6; b G6PD; c FN1; d IGFBP1; e IGFBP3; f KIM1; g GCLC; h
GSTM1; i KLK1
Table 4 Correlation of log normalized gene fold changes with established biomarkers, serum creatinine and estimated GFR in the
CKD group
CYP2D6 G6PD FN1 IGFBP1 IGFBP3 KIM1 GCLC GSTM1 KLK SrCr eGFR
SrCr Pearson Correlation 0.156 −0.491 −0.354 0.233 0.438 0.369 −0.383 0.280 0.515 1.000 −0.858a
Sig. (2-tailed) 0.594 0.075 0.215 0.424 0.118 0.194 0.176 0.333 0.059 - 0.000
N 14 14 14 14 14 14 14 14 14 14 14
eGFR Pearson Correlation −0.028 0.179 0.405 0.109 −0.472 −0.062 0.235 −0.386 −0.280 −0.858a 1.000
Sig. (2-tailed) 0.925 0.540 0.151 0.711 0.088 0.833 0.419 0.173 0.333 0.000 -
N 14 14 14 14 14 14 14 14 14 14 14
aCorrelation is significant at the 0.01 level (2-tailed)
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seen in the CKD group in between the study genes
and serum creatinine. In the CKDu group, FN1 and
IGFBP3 had negative correlations with serum creatin-
ine (r = −0.445, p = 0.008 and r = −0.389, p = 0.023 re-
spectively) whereas KIM1 and IGFBP1 showed
positive correlations (r = 0.369, p = 0.032 and r = 0.373,
p = 0.030 respectively) with serum creatinine. IGFBP1,
KIM1 and KLK1 showed negative correlations with
eGFR (r = −0.513, p = 0.002; r = −0.443, p = 0.009; r =
−0.340, p = 0.049 respectively). The other genes did
not show any correlation of significance. In the CKD
group, none of the genes showed any significant cor-
relation with serum creatinine or eGFR.
There was no statistical difference seen in the two-
tailed ttest between the male and female populations
within each study group.
Discussion
We analyzed the expression patterns of a selected panel
of genes in CKDu patients to test their possible use as
early screening and prognostic biomarkers. In an era
where personalized medicine is taking precedence over
Table 5 Correlation of log normalized gene fold changes with established biomarkers, serum creatinine and estimated GFR in the
CKDu group
CYP2D6 G6PD FN1 IGFBP1 IGFBP3 KIM1 GCLC GSTM1 KLK SrCr eGFR
SrCr Pearson Correlation 0.077 0.041 −0.445a 0.373b −0.389b .0369b 0.105 −0.024 0.190 1.000 −0.743a
Sig. (2-tailed) 0.666 0.820 0.008 0.030 0.023 0.032 0.554 0.891 0.282 - 0.000
N 34 34 34 34 34 34 34 34 34 34 34
eGFR Pearson Correlation −0.141 −0.055 0.320 −0.513a 0.408* −0.443a −0.110 −0.150 −0.340b −0.743a 1.000
Sig. (2-tailed) 0.426 0.758 0.065 0.002 0.017 0.009 0.536 0.396 0.049 0.000 -
N 34 34 34 34 34 34 34 34 34 34 34
aCorrelation is significant at the 0.01 level (2-tailed)
bCorrelation is significant at the 0.05 level (2-tailed)
All entries in boldface are significant at least at the 0.05 level
Fig. 2 Correlation graphs of serum creatinine with log normalized gene expressions of a CYP2D6; b G6PD, c FN1; d IGFBP1; e IGFBP3; f KIM1; g
GCLC; h GSTM1; i KLK1 in CKD patients
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generalized diagnosis and treatment, the use of personal-
ized biomarkers to identify specific molecular changes
occurring in an individual is becoming more important
[37, 38]. Although personalization to the individual level
would not be financially feasible for developing coun-
tries, it is necessary to at least get specific to the disease
level. For a disease like CKD, although there are some
common pathways that lead to the progression of the
disease, there are various primary causes having different
pathophysiological mechanisms [2] and it would be ad-
vantageous to have biomarkers personalized to identify,
monitor and treat them specifically.
This need is further realized in CKDu, a disease which
is limited only to specific populations in certain geo-
graphic locations of the world. Although biomarkers of
general CKD such as proteinuria, serum creatinine and
GFR are currently being used in the diagnosis and prog-
nosis of CKDu [10], this disease is believed to have a dif-
ferent, unidentified etiology, and therefore should give
rise to different molecular level changes in the individual
leading to the disease. In a geographical location en-
demic to CKDu, where individuals are exposed to similar
environments as well as may be having diagnoses of
other metabolic diseases, it can be easy to misdiagnose
patients using common biomarkers and this brings a ne-
cessity to identify biomarkers to differentiate the groups
from each other while also separating them from healthy
individuals.
The symptoms of CKD usually do not become appar-
ent till significant reduction of the kidney function has
occurred. Stages 1 to 3 of the disease have been classi-
fied as early stage because of their asymptomatic pro-
gression and due to the fact that progression of the
disease can be altered and complications reduced if
identified during these stages [39]. Stages 4 and 5 have
extensive kidney damage and usually lead to end-stage
renal failure and therefore were considered as late stages
of the disease.
In this study, analysis of gene expression was made
using healthy population from Kandy, Sri Lanka; an area
not endemic to the disease, as calibrators. These individ-
uals belong to the same ethnicity and race, however
were not residing in the same environment and were not
involved in farming as an occupation. The study popula-
tion had more males than females. The increased risk
and incidence of CKDu in males has also been docu-
mented by other epidemiological studies [10, 11]. Any
potential biomarker identified was expected to be
Fig. 3 Correlation graphs of serum creatinine with log normalized gene expressions of a CYP2D6; b G6PD, c FN1; d IGFBP1; e IGFBP3; f KIM1; g
GCLC; h GSTM1; i KLK1 in CKDu patients
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significantly differentially expressed in the diseased
groups. A healthy group from the CKDu endemic area,
Girandurukotte, was also included in the study. As the
etiology for the disease is believed to be environmental
related, this population is also possibly exposed to the
same disease causing factor/s and have to be considered
a population at risk of developing disease. The gene ex-
pression patterns of this group were also thus compared
to the healthy group from Kandy.
The fold changes observed in the CKD groups, both
early and late stages, had high variation and therefore
high standard errors as seen in Fig. 1. This could be due
to the limited size of the CKD study population (n = 14)
and the different etiologies for CKD within our study
group, including hypertension (n = 8), diabetes (n = 3),
and both (n = 3). The gene expression patterns of the
CKD group also did not show any correlation with the
currently used markers of the disease, serum creatinine
and eGFR.
The CKDu group however showed lower standard er-
rors and had fold changes of significant difference to the
Kandy healthy group for some of the genes. Significant
difference was observed between the KH group and early
stage CKDu for the gene IGFBP1 (p = 0.012). IGFBP1
levels in human plasma has shown dynamic metabolic
regulation [40]. Of the IGF binding proteins, IGFBP1
has been found to be the most regulated due to its acute
down regulation by insulin and up regulation by glucor-
egulatory hormones and cytokines [16]. This gene is the
main regulator of IGF-1 bioactivity and it has been
found to play a major role in the development of dia-
betes and associated complications [41]. Low circulating
serum levels of this enzyme has been associated with
type 2 diabetes (T2D) in studies conducted in Swedish
population [42–44] as well as in an Indian population
[45]. Although our CKDu population was not diagnosed
with diabetes, the IGFBP1 was most down regulated in
the early stage CKDu, more so even than the CKD
groups.
A similar difference was also observed between the
KH group and early stage CKDu for the KIM1 gene (p =
0.003). The KIM1 gene was seen down regulated in the
early stage CKDu patients when compared to the KH
group. The KIM1 protein has been extensively studied
and has been identified as a new specific marker for
proximal tubule injury [46]. The protein and the gene
have however been studied mainly in urine and kidney
tissue biopsies, where it has always been up regulated
with kidney disease [46–48].
Our finding in blood tissue is contrasting where it was
seen down regulated in most of the diseased patients,
with a highly significant decrease seen in the early stage
CKDu patients. The role of KIM1 gene in blood is differ-
ent to that of the kidney. The gene shares different
names including Hepatitis A virus cellular receptor 1
(HAVCRI) and T-cell immunoglobulin and mucin do-
main (TIM1) [49, 50], owing to their different functions.
Their functions mainly include coding for membrane re-
ceptors and associated with inflammatory healing re-
sponse and infection [50]. Although it is difficult to
assume the importance or the physiological response of
this gene in blood of these diseased patients, the signifi-
cant decrease seen in the early stage of CKDu indicates
its potential as an early marker of the disease which
needs to be further tested.
Significant differences in between the healthy popula-
tions from the two areas were seen for the G6PD,
GCLC, GSTM1 and KIM1 genes, where the GH popula-
tion showed similar expression patterns to that of the
disease groups for the GCLC, GSTM1 and KIM1 genes.
The healthy individuals of the GH group were those not
diagnosed with CKDu on routine screening of popula-
tion. However, as the initial stages of disease do not
show any symptoms and there is a lack of sensitive early
markers, the individuals from the GH group could be in
the very early stages of disease formation, being resi-
dents of the high risk area. Follow up of these individ-
uals and clinical testing could help answer these
questions. If these individuals do indeed progress to dis-
ease formation, these genes would hold high potential as
early diagnostic biomarkers.
Up regulation of the GCLC and GSTM1 genes in the
Girandurukotte healthy population compared to Kandy
healthy population has been documented in a separate
cohort [51] and has been hypothesized to be due to the
environmental oxidative stressors that the population
may be exposed to. These genes therefore hold potential
as early screening markers, but needs further follow-up
and testing.
When correlating gene expressions with the existing
markers of CKD/CKDu, FN1 and IGFBP3 had negative
correlations with serum creatinine whereas KIM1 and
IGFBP1 showed positive correlations. IGFBP1, KIM1
and KLK1 showed negative correlations with eGFR. FN1
gene showed a significant negative correlation with
serum creatinine in the CKDu patients. This gene was
up regulated in all the disease patients but was seen to
be more highly expressed in the early stage CKDu than
late stage CKDu, and early stage CKD than late stage
CKD. The correlation of the gene expressions with the
current biomarkers of kidney diseases further
strengthens their potential use as biomarkers of CKDu.
The significant correlations of FN1, IGFBP1, IGFBP3
and KIM1 with serum creatinine and IGFBP1, KIM1
and KLK1 with eGFR in the CKDu patients indicates
that these genes have a contributory factor to disease
progression in this study group. Decrease of KIM1 and
IGFBP1 expressions was seen in early stages of the
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disease with levels rising back to near Kandy healthy
with later stages. Girandurukotte healthy individuals
were also seen to have decreased expression of these
genes similar to the early stages of disease (Fig. 1). It
could be therefore postulated that the reduced baseline
expression of these genes relates to disease susceptibility
in this endemic population. The KIM1 and IGFBP1 gene
also showed statistically significant difference in expres-
sion between the early and late stages of CKDu in the
one-way ANOVA test further strengthening their possi-
bility as prognostic biomarkers of CKDu.
The serum creatinine values were not obtained from
the healthy individuals and therefore the correlation was
based on values obtained only from disease patients.
The expressions of the genes did not seem to have a
steady progression with increasing severity of the disease
as is seen with the established biomarkers. Drastic differ-
ential regulation was seen in the early stage CKDu com-
pared to the KH group and the fold changes were near
normal in the later stages of CKDu as seen in FN1,
IGFBP1 and KIM1 genes. The expression of these genes
from healthy through the increasing stages may not
therefore be linear as in the case of serum creatinine,
and the correlations seen may not indicate a relationship
between the parameters, but individually regulatory
mechanisms. For example, FN1 expression in blood has
been associated with hypertension where increased ex-
pression was seen in hypertensive patients, being in-
volved in protective mechanisms that limit organ
damage [52]. The increased expression in early stage
CKDu could be an initial protective effect which again
diminishes with disease progression.
As a single biomarker will not suffice for clear identifi-
cation of this disease with multiple possible etiologies
and comorbidities, a panel of markers will have to be
used. IGFBP1 and KIM1 genes have potential as early
screening markers of CKDu as they showed significant
differences in expression with late stage CKDu and the
KH group. Increased expression of GCLC could be an
indicator of environmental oxidative stress and the lack
of GSTM1 gene is an indicator of increased susceptibil-
ity to oxidative stress. IGFBP1, IGFBP3, FN1 and KIM1
showed correlations with serum creatinine whereas
IGFBP1, KIM1 and KLK1 showed correlations with
eGFR therefore holding potential as progressive bio-
markers of CKDu.
Limitations of study
The study was a preliminary one looking at the possibil-
ity of selected genes as genetic biomarkers of CKDu.
The study was carried out with a limited sample size for
the identification of possible biomarkers with significant
variances, which could then be validated in further stud-
ies with larger study populations. The healthy and
disease groups belonged to different age categories
which could be an influencing factor to the results.
Conclusion
A panel consisting of IGFBP1, KIM1, GCLC and
GSTM1 genes could be used in combination for early
screening of CKDu, whereas these genes in addition with
FN1, IGFBP3 and KLK1 could be used to monitor pro-
gression of CKDu. This is however a pilot study and the
regulation of these genes have to be studied on larger
scale populations to identify robust biomarkers that
could be further tested for clinical use.
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